Literature DB >> 9175783

Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A-like enzyme.

H Ostrowska1, C Wojcik, S Omura, K Worowski.   

Abstract

Lactacystin, the most specific inhibitor of the proteasome, strongly inhibited at pH 5.5 the activity of human platelet lysosomal cathepsin A-like enzyme. At a concentration as low as 1-5 microM it almost completely decreased the hydrolysis rate of cathepsin A specific substrates: Cbz-Phe-Ala and FA-Phe-Phe. This inhibition was probably due to the lactacystin intermediate beta-lactone formed during 10 min hydrolysis at pH 8.0 since nonhydrolyzed inhibitor did not affect cathepsin A activity. Basing on similarities in the inhibitor sensitivity, pH optimum, and substrate preferences it is suggested that the cathepsin A-like activity may be involved in chymotrypsin-like activity of the proteasome.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9175783     DOI: 10.1006/bbrc.1997.6434

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  27 in total

1.  The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses.

Authors:  K Schwarz; R de Giuli; G Schmidtke; S Kostka; M van den Broek; K B Kim; C M Crews; R Kraft; M Groettrup
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

Review 2.  The ubiquitin-proteasome pathway and proteasome inhibitors.

Authors:  J Myung; K B Kim; C M Crews
Journal:  Med Res Rev       Date:  2001-07       Impact factor: 12.944

3.  Proteasome inhibitors block a late step in lysosomal transport of selected membrane but not soluble proteins.

Authors:  P van Kerkhof; C M Alves dos Santos; M Sachse; J Klumperman; G Bu; G J Strous
Journal:  Mol Biol Cell       Date:  2001-08       Impact factor: 4.138

4.  Proteasomes and ubiquitin are involved in the turnover of the wild-type prion protein.

Authors:  Y Yedidia; L Horonchik; S Tzaban; A Yanai; A Taraboulos
Journal:  EMBO J       Date:  2001-10-01       Impact factor: 11.598

5.  Structural and functional characterization of the USP11 deubiquitinating enzyme, which interacts with the RanGTP-associated protein RanBPM.

Authors:  Haruko Ideguchi; Atsuhisa Ueda; Masatsugu Tanaka; Jun Yang; Takashi Tsuji; Shigeru Ohno; Eri Hagiwara; Akiko Aoki; Yoshiaki Ishigatsubo
Journal:  Biochem J       Date:  2002-10-01       Impact factor: 3.857

6.  The formation of peripheral myelin protein 22 aggregates is hindered by the enhancement of autophagy and expression of cytoplasmic chaperones.

Authors:  Jenny Fortun; Jonathan D Verrier; Jocelyn C Go; Irina Madorsky; William A Dunn; Lucia Notterpek
Journal:  Neurobiol Dis       Date:  2006-12-13       Impact factor: 5.996

7.  Proteasome proteolysis supports stimulated platelet function and thrombosis.

Authors:  Nilaksh Gupta; Wei Li; Belinda Willard; Roy L Silverstein; Thomas M McIntyre
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-10-31       Impact factor: 8.311

8.  The ubiquitin-proteasome system plays an important role during various stages of the coronavirus infection cycle.

Authors:  Matthijs Raaben; Clara C Posthuma; Monique H Verheije; Eddie G te Lintelo; Marjolein Kikkert; Jan W Drijfhout; Eric J Snijder; Peter J M Rottier; Cornelis A M de Haan
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

9.  Role of proteases in the pathophysiology of cardiac disease.

Authors:  Raja B Singh; Sucheta P Dandekar; Vijayan Elimban; Suresh K Gupta; Naranjan S Dhalla
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

10.  Peptide and Peptide-Like Modulators of 20S Proteasome Enzymatic Activity in Cancer Cells.

Authors:  Carlos García-Echeverría
Journal:  Int J Pept Res Ther       Date:  2006-03-04       Impact factor: 1.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.